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Dysfunction and loss of insulin-producing pancreatic
b cells represent hallmarks of diabetes mellitus. Here,
we show that mice lacking the mitogen-activated
protein kinase (MAPK) p38d display improved
glucose tolerance due to enhanced insulin secretion
from pancreatic b cells. Deletion of p38d results in
pronounced activation of protein kinase D (PKD),
the latter of which we have identified as a pivotal regu-
lator of stimulated insulin exocytosis. p38d catalyzes
an inhibitory phosphorylation of PKD1, thereby atten-
uating stimulated insulin secretion. In addition, p38d
null mice are protected against high-fat-feeding-
induced insulin resistance and oxidative stress-
mediated b cell failure. Inhibition of PKD1 reverses
enhanced insulin secretion from p38d-deficient islets
and glucose tolerance in p38d null mice as well as
their susceptibility to oxidative stress. In conclusion,
the p38d-PKD pathway integrates regulation of the
insulin secretory capacity and survival of pancreatic
b cells, pointing to a pivotal role for this pathway in
the development of overt diabetes mellitus.
INTRODUCTION
Diabetes results from insufficient (absolute or relative) insulin
secretion. In type 1 diabetes, the insulin-producing b cells are
destroyed by an autoimmune attack (von Herrath et al., 2007).
Type 2 diabetes is often linked to obesity-related insulin resis-tance, which initially is compensated by enhanced capacity of
b cells to secrete insulin. However, in a large subset of obese
and insulin-resistant individuals, these compensatory mecha-
nisms are impaired, leading to reduced b cell mass and function
and culminating in manifest diabetes (Kahn et al., 2006). b cell
damage and insulin resistance appear to be at least partially trig-
gered by inflammatory, oxidative, and endoplasmic reticulum
stress-induced pathways including the mitogen-activated
protein kinase (MAPK) signaling cascade (Wellen and Hotamisli-
gil, 2005). Indeed, activation of the MAPK c-jun N-terminal
kinase (JNK) represents a central signal transduction event
promoting peripheral insulin resistance, suppressing insulin
production and secretion, and increasing apoptosis of islet cells
(Hirosumi et al., 2002; Kaneto et al., 2004).
The role of the p38MAPKs (which are closely related to JNK) in
these processes remains poorly understood. p38 activity has
been reported to be increased in insulin-resistant peripheral
tissues from diabetic patients (Koistinen et al., 2003). Moreover,
in vitro data have demonstrated that p38 activation upon expo-
sure to TNF-a, free fatty acids, and oxidative stress impairs
insulin signaling in adipocytes and skeletal muscle cells through
mechanisms very similar to those described for JNK (de Alvaro
et al., 2004). Finally, activation of p38 appears to trigger pancre-
atic b cell dysfunction and apoptosis in response to oxidative
stress and cytokines in vitro (Makeeva et al., 2006). Verification
of an involvement of p38 in metabolic diseases in vivo is compli-
cated by the existence of four different p38 genes, p38a, p38b,
p38g, and p38d.
To date, the best-characterized p38 isoform is p38a. It has
been shown that p38a knockout mice die at midgestation, likely
because of a defective placental organogenesis (Adams et al.,
2000; Mudgett et al., 2000; Tamura et al., 2000). Recently, itCell 136, 235–248, January 23, 2009 ª2009 Elsevier Inc. 235
has been demonstrated that p38a is a fundamental regulator of
cellular proliferation and carcinogenesis in vivo (Hui et al., 2007;
Ventura et al., 2007). p38a is also required to mediate an inflam-
matory response in macrophages (Kang et al., 2008). On the
basis of inhibitor studies, it was postulated that p38a and p38b
functionally cooperate in the context of inflammatory processes.
However, p38b-specific knockout mice revealed no differences
in several in vivo and in vitro models of inflammation (Beardmore
et al., 2005).
The least-characterized isoforms are p38g and p38d. p38g is
predominantly expressed in skeletal muscle and heart, and
p38g-deficient myoblasts exhibited an attenuated cell-to-cell
fusion capacity in vitro (Perdiguero et al., 2007). The isoform
p38d shares approximately 60% homology with the other p38
family members and about 40% homology with other MAPKs.
Like p38a, p38d is activated by various stress stimuli, including
inflammatory cytokines and oxidative stress (Jiang et al.,
1997). Recent in vitro studies have demonstrated that p38d
might be involved in keratinocyte differentiation and PKCd-
dependent keratinocyte apoptosis (Efimova et al., 2004), as
well as the progression of neurodegenerative disorders referred
to as tauopathies (Feijoo et al., 2005). However, no specific
in vivo functions of p38d have been reported thus far.
To address such functions, we generated p38d null mice.
Remarkably, these mice displayed improved glucose tolerance
due to enhanced insulin exocytosis from pancreatic b cells.
Moreover, inactivation of p38d protected against hyperlipid-
emia-induced insulin resistance and oxidative stress-imposed
b cell apoptosis. At the molecular level, we discovered that
p38d exerts an inhibitory phosphorylation on protein kinase D 1
(PKD1), a kinase that regulates both stimulated insulin secretion
and pancreatic b cell survival. We propose that p38d represents
a critical regulator of glucose homeostasis in vivo.
RESULTS
Enhanced Glucose Tolerance in p38d Null Mice Due
to Increased Insulin Exocytosis from Pancreatic b Cells
To address in vivo functions of p38d in metabolism, we generated
p38d floxed mice and crossed them with protamine promoter-
drivenCre recombinase-expressingmice, amalegermlinedeleter
strain (O’Gorman et al., 1997). With this approach, we obtained
p38d null mice (p38dD/D mice) and corresponding wild-type
control littermates (p38d+/+ mice) (Figure S1 available online).
p38dD/D mice presented with normal general health, viability,
fecundity, body composition, and body weight (data not shown).
Assessment of the expression of p38d in organs involved in
glucose homeostasis revealed that p38d was abundantly ex-
pressedbothat themRNAandprotein level and insimilar amounts
in the exo- and endocrine pancreas. In contrast, no expression of
p38d was observed in insulin-sensing organs such as adipose
tissue and liver. Very low amounts of p38dmRNA were detected
in skeletal muscle (Figure 1A and Figure S2A).
The observed expression pattern prompted us to investigate
the role of p38d in glucose homeostasis. p38dD/D mice fasted
for 16 hr showed a significantly enhanced glucose tolerance
compared to p38d+/+ mice (Figure 1B), while insulin sensitivity
was equal in p38dD/D and p38d+/+ mice (Figure S2B). Although236 Cell 136, 235–248, January 23, 2009 ª2009 Elsevier Inc.lower glucose levels were attained in p38dD/D mice after the
glucose challenge, circulating insulin levels were increased
compared to p38d+/+ control mice. The glucose challenge
elicited a biphasic insulin response; both initial first phase and
subsequent second phase were enhanced in p38dD/D mice
(Figure 1C).
Enhanced insulin release in p38dD/D mice was not the conse-
quence of alterations in the b cell mass, in the pancreatic islet
architecture, or in insulin content (Figure S3). Transmission elec-
tron microscopy further revealed that the volume density and
distribution of both pale (immature) and dense core (mature)
secretory granules were similar in b cells in islets of p38d+/+
and p38dD/D mice (Table S1).
To test whether enhanced insulin secretion in p38dD/D mice
primarily reflects an intrinsic islet/b cell effect that is independent
of the action of incretins or innervation, we isolated pancreatic
islets from p38dD/D and p38d+/+ mice and tested their capacity
to secrete insulin in vitro. Knockout islets released more insulin
both under basal (2.8 mM glucose) and glucose-stimulated
(16.7 mM glucose) conditions compared to control islets
(Figure 1D). By contrast, glucagon secretion was unaffected in
p38dD/D islets, and high glucose (16.7 mM) inhibited the release
of the hormone to the same extent in both wild-type and
knockout islets (Figure 1E). These data suggest that lack of
p38d improves glucose tolerance and enhances insulin secretion
by a direct and b cell-specific mechanism.
Enhanced Insulin Exocytosis in p38d-Deficient
Pancreatic b Cells Is Independent of Differences
in Glucose Metabolism, KATP Closure, and Ca
2+ Influx
We next addressed at which step p38d interferes with the insulin
secretory pathway in pancreatic b cells. In p38dD/D islets, insulin
secretion elicited by either 20mMKCl (to evoke depolarization of
membrane) or 100 mM tolbutamide (to close ATP-regulated K+
channels and elicit electrical activity) was enhanced compared
to control islets (Figure 1D).
To determine whether ablation of p38d affects Ca2+ influx, we
measured intracellular calcium concentrations ([Ca2+]i) in
response to glucose and KCl in islets isolated from p38dD/D
and p38d+/+ mice. The average [Ca2+]i was similar in the two
groups of islets both under basal conditions (2.8 mM glucose)
and after stimulation by either glucose (16.7 mM) or KCl
(20 mM in the presence of 2.8 mM glucose) (Figures S4A and
S4B). Likewise, whole-cell Ca2+ currents were comparable in
single b cells of p38dD/D and p38d+/+ littermates (Figures S4C
and S4D). The fact that insulin secretion was enhanced in
p38dD/D islets despite similar [Ca2+]i levels suggests that p38d
acts directly at the level of exocytosis.
To address whether exocytosis is enhanced in p38d-deficient
b cells, we performed high-resolution capacitance measure-
ments of exocytosis on single b cells (Gopel et al., 2004). A train
of ten depolarization steps from 70 mV to 0 mV evoked larger
responses in p38dD/D than in control b cells, resulting in a
2-fold larger increase of membrane capacitance in p38dD/D cells
(Figures 2A and 2B). Exocytosis was enhanced approximately
equally in p38dD/D compared to p38d+/+ b cells throughout
the trains of depolarization. The rate of capacitance increase in
cells lacking p38d was also higher than that of wild-type cells
when exocytosis was elicited by clamping [Ca2+] at 1.5 mM,
a condition that bypasses any effects on Ca2+ entry (Figures
2C and 2D). Collectively, these results indicate that the
enhanced insulin secretion from p38d-deficient islets is not
caused by differences in glucose metabolism, KATP closure, or
[Ca2+]i homeostasis between knockout and control b cells.
Rather, ablation of p38d influences insulin secretion by a direct
effect on the exocytotic machinery that is exerted downstream
of [Ca2+]i elevation.
p38d Exerts an Inhibitory Phosphorylation
on Protein Kinase D 1
We next investigated a possible molecular mechanism by which
p38d attenuates insulin exocytosis using an unbiased proteomic
approach. We ectopically expressed a hemagglutinin (HA)-
tagged constitutively active form of p38d, obtained by substitu-
tion of phenylalanine 324 with serine (F324S) as previously
described (Askari et al., 2007), in 293T cells. Constitutive activity
was tested in an in vitro kinase assay using recombinant HIS-
tagged ATF-2 as a substrate (Figure S5A). HA immunoprecipi-
tates fromHA-p38dF324S and HA-expressing cells were analyzed
by liquid chromatography-tandem mass spectrometry (LC-MS/
MS). A number of putative interactors were obtained among
which protein kinase D 1 (PKD1) wasmost frequently found (rep-
resented by a total of 36 unique peptides) (Table S2). PKD is
necessary for biogenesis of trans-Golgi network (TGN) to cell
surface transport carriers (Bard and Malhotra, 2006) and has
been shown to be a positive regulator of secretion in
Figure 1. Mice Lacking p38d Show Improved Glucose Tolerance and Enhanced Insulin Secretion
(A) Western blotting revealed expression of p38d in wild-type (+/+) pancreas but not in liver (Li), skeletal muscle (Sk), andwhite (Wa) and brown (Ba) adipose tissue
compared to tissues from p38d null (D/D) mice. Coomassie blue staining was used to confirm equal loading.
(B) Glucose tolerance test (GTT) in mice with the indicated genotypes (*p < 0.05, **p < 0.01).
(C) Parallel measurements of serum insulin during the GTT in mice with the indicated genotypes (*p < 0.05).
(D) Insulin release in response to indicated stimuli (Glc, glucose; KCl, potassiumchloride; tolb., tolbutamide) in isolated isletswith the indicated genotypes (*p < 0.05).
(E) Glucagon secretion in response to 2.8 mM and 16.7 mM glucose in islets isolated with the indicated genotypes (ns, not significant).
All error bars indicate ± SEM.Cell 136, 235–248, January 23, 2009 ª2009 Elsevier Inc. 237
Figure 2. Enhancement of Exocytosis in p38d-Deficient Pancreatic b Cells Occurs Downstream of Calcium Influx
(A) A train of ten successive 500ms depolarizations from70 to 0mV increased capacitance (in femtofarad [fF]) in pancreatic b cells with the indicated genotypes
(*p < 0.05).
(B) Average cumulative increase of capacitance (*p < 0.05).
(C) Changes in cell capacitance (Cm) when exocytosis was elicited by intracellular application of 1.5 mM free [Ca
2+]i via the recording electrode capacitance in
pancreatic b cells with the indicated genotypes. Values have been normalized to the resting cell capacitance (Cm,0), which was 4.6 ± 0.4 pF (n = 8) and 4.6 ±
0.2 pF (n = 16) in p38dD/D and p38d+/+ cells, respectively. Data are presented as the mean values (central lines) and ± SEM (shaded areas).
(D) Steady-state average rate of capacitance change (in fF/s) for cells measured over a 60 s period (*p < 0.05).
All error bars indicate ± SEM.neuroendocrine cells (Li et al., 2004). The interaction between
p38d and PKD1 was confirmed by coimmunoprecipitation
experiments in 293T cells (Figure S5B). HA pulldowns also con-
tained endogenous PKD1 in INS1 cells (rat insulinoma-derived
pancreatic b cell line) stably expressing HA-p38dF324S but not
in cells expressing HA alone (Figure 3A).
We then tested the ability of p38d to directly phosphorylate
PKD1 in vitro. Active recombinant p38d phosphorylated immu-
noprecipitated human GFP-tagged wild-type PKD1 (GFP-
PKD1-WT) and kinase-deadPKD1 (GFP-PKD1-KD) (Figure S5C),
as well as Sf9 cell-derived (Figure S5D) and E. coli-expressed
recombinant human GST-PKD1 (Figure 3B). Bacterial PKD1
showed high basal activity that caused high autophosphoryla-
tion. However, enhancement of phosphorylation by addition of
p38d became more evident when the PKD inhibitor Go¨6976
was added to the reactions to reduce autophosphorylation.
The LC-MS/MS analysis of in vitro phosphorylated immunopre-
cipitated murine GST-PKD1 identified an autophosphorylation
and a 14-3-3 binding site (Ser203 and Ser206) (Zhang et al.,
2005), one of the activating dual phosphorylation sites (Ser748),238 Cell 136, 235–248, January 23, 2009 ª2009 Elsevier Inc.and a protein kinase C-dependent transphosporylation site
(Ser255) (Vertommen et al., 2000) (Figure S6). p38d specifically
phosphorylated Ser403, a p38 MAPK consensus site (SP/TP),
as well as the closely located Ser407 residue (Figure S7). LC-
MS/MS analysis of the HA-p38dF324S immunoprecipitates from
293T cells confirmed Ser403 phosphorylation on endogenous
PKD (data not shown). Both phosphorylation sites are conserved
between mouse (Ser403 and Ser407), rat, and human (Ser397 and
Ser401) and can be found in PKD1 and PKD3 but not in PKD2
(Figure 3C). PKD1 is the predominant isoform expressed in
pancreatic b cells (data not shown).
We next generated the corresponding single and double
serine to alanine mutants of kinase-dead PKD1 and double
serine to alanine mutants of wild-type PKD1 (GFP-PKD1-AA),
as well as double serine to aspartate mutants of wild-type
PKD1 (GFP-PKD1-DD). Mutations of either Ser397 or Ser401 to
alanines significantly reduced p38d-dependent phosphorylation
in vitro, and mutation of both sites diminished autoradiography
almost to background levels (Figure 3D). The ability of kinases
to phosphorylate the substrate CREBtide was assayed in vitro.
Figure 3. p38d Interacts with PKD1 and Phosphorylates It at Ser 397 and 401
(A)Western blot with indicated immunoprecipitates (IP) andwhole-cell extracts (WCE) from INS1 cells stably transfectedwith indicated constructs confirms phys-
ical interaction with endogenous PKD1 (*unspecific band).
(B) In vitro kinase assay with and without recombinant p38d and recombinant E. coli-derived GST-tagged PKD1 in the presence and absence of the PKC inhibitor
Go¨6976.
(C) Sequence alignment of the region around S403-407 of mouse PKD1, PKD3, and PKD2, as well as human and rat PKD1. Conserved residues (S403-407 in
mPKD1, S397-401 in hPKD1) are indicated by rectangles.
(D) In vitro kinase assay with recombinant p38d and indicated immunoprecipitated proteins. Quantification of autoradiography with corresponding bars posi-
tioned under bands (*p < 0.05).
(E) In vitro kinase assaywith indicated immunoprecipitated proteins using CREBtide as a substrate. CREBtide was spotted, while immunopreciptateswere tested
for equal loading by western blotting. Quantification of radiography using a scintillation counter with corresponding bars positioned under spots (*p < 0.05).
All error bars indicate ± SEM.Autoradiography of spotted CREBtide from reactions with GFP-
PKD1-KD was markedly reduced compared to reactions with
GFP-PKD1-WT, while no signal could be detected with CREB-
tide from reactions with GFP only. Importantly, CREBtide autora-
diography from reactions containing GFP-PKD1-AA was
enhanced, whereas it was markedly reduced in reactions withGFP-PKD1-DD compared to reactions with GFP-PKD1-WT.
Quantification of radiography of purified CREBtide with a scintil-
lation counter confirmed respective kinase activities (Figure 3E).
These results suggest that PKD1 is a direct substrate of p38d and
that p38d-dependent phosphorylation of PKD1 constitutes an
inhibitory modification.Cell 136, 235–248, January 23, 2009 ª2009 Elsevier Inc. 239
Figure 4. Increased Activity of PKD Leads to Altered Golgi Organization in p38d-Deficient b Cells
(A) Activity of protein kinase D (PKD) was determined by western blotting with an antibody against the activatory phosphorylation sites (serines 744 and 748) (BG,
basal glucose and SG, stimulatory glucose levels). Immunoblotting with an antibody against Actin was used to determine equal loading of phopho-PKD and total
PKD1 blots.
(B) Immunofluorescence with antibodies against giantin (red) in pancreatic b cells with the indicated genotypes.
(C) Immunofluorescence with antibodies against giantin (red) in INS1 cells stably expressing HA or HA-p38dF324S cultured in the presence of stimulatory glucose.
Expression of p38dF324S led to formation of tubular protrusions from the Golgi complex (arrows).
(B and C) Dashed boxes outline the areas that were magnified. Nuclear DNA was stained with DAPI (blue). Scale bars represent 10 mm.Enhanced Activity of PKD and Altered Golgi
Organization in Pancreatic b Cells Lacking p38d
We proceeded to test whether lack of p38d results in increased
activity of PKD in pancreas by assessing PKD autophosphoryla-
tion (serine 916). The activity was markedly enhanced in p38dD/D
compared to p38d+/+ pancreas (Figure S8). To confirm increased
PKD activity in b cells, we generated MIN6 cells (murine insuli-
noma-derived pancreatic b cell line) stably expressing small hair-
pins (shRNA) against p38d. Consistently, lack of p38d enhanced
insulin secretion also inMIN6 cells (see below). Indeed, amarked
increase in activatory PKD phosphorylation was also observed in
MIN6 cells lacking p38d compared to control cells, which was
further increased in p38d-deficient cells stimulated by glucose
(Figure 4A).
Activation of PKD induces membrane fission at the TGN,
which can be monitored by altered localization of Golgi marker
proteins by immunofluorescence (Bossard et al., 2007; Liljedahl
et al., 2001). Indeed, the Golgi markers giantin, furin convertase,240 Cell 136, 235–248, January 23, 2009 ª2009 Elsevier Inc.and GM130 exhibited a diffuse distribution in p38dD/D primary
pancreatic b cells, whereas a characteristic crescent-shaped
staining was found in p38d+/+ cells (Figure 4B and Figure S9).
Altered Golgi organization was confirmed in MIN6 cells lacking
p38d by immunofluorescence stainings of giantin (Figure S10).
Conversely, INS1 cells ectopically expressing HA-p38dF324S
showed tubular protrusions from the Golgi apparatus reminis-
cent of inhibited TGN membrane fission (Figure 4C). The latter
cellular phenotype correlated with suppressed stimulated insulin
secretion in INS1 cells (see below). Collectively, these data indi-
cate that lack of p38d leads to constitutive PKD activity and
enhanced membrane fission at the TGN in pancreatic b cells,
whereas increased p38d activity has the opposite effects.
Inhibitors of Phospolipase C and Conventional PKCs
Restore Insulin Secretion in p38d-Deficient Islets
Generation of diacylglycerol (DAG) by phosphatidyl-inositol-
specific phospholipases C (PI-PLCs; PLC, phospolipase C)
Figure 5. Restoration of Insulin Secretion in p38dD/D Islets and Glucose Tolerance in p38dD/D Mice by Pharmacological Inhibition of PKD
(A) Immunofluorescence using antibodies against giantin (red) in pancreatic b cells with the indicated genotypes exposed to Go¨6976 (Go) or U73122 (U) as indi-
cated. Nuclear DNA was stained with DAPI (blue). Dashed boxes outline the areas that have been magnified. The scale bar represents 10 mm.
(B) Glucose (16.7 mM)-stimulated insulin secretion from islets with the indicated genotypes exposed to DMSO, U73122, and Go¨6976 (*p < 0.05).
(C) Glucose tolerance test (GTT) in mice with the indicated genotypes treated with DMSO or U73122 as indicated (*p < 0.05).
All error bars indicate ± SEM.activates PKD, which is subsequently recruited to the TGN,
where it promotes membrane fission (Diaz Anel, 2007). Pharma-
cological inhibition of this pathway is expected to reverse cellular
phenotypes and related effects caused by deletion of p38d. To
test this, we used the PI-PLC inhibitor U73122 and Go¨6976,
a potent inhibitor of PKD and conventional protein kinases C
(PKCs) (Haxhinasto and Bishop, 2003). Both U73122 and
Go¨6976 resulted in relocalization of giantin to the TGN in
p38dD/D pancreatic b cells, whereas none of the compounds
altered normal localization of giantin in p38d+/+ cells (Figure 5A).
These cellular effects echoed those on glucose-evoked
(16.7 mM) insulin secretion: none of the compounds had any
effect on insulin secretion from p38d+/+ islets, but the enhance-
ment seen in p38dD/D islets was abolished (Figure 5B). Impor-
tantly, peritoneal injections of U73122 decreased glucose toler-
ance of p38dD/D mice to that observed in dimethyl sulfoxide
(DMSO)-treated p38d+/+ controls, without modifying glucose
tolerance of the control animals (Figure 5C). Thus, inhibition of
PKD reverses the effects of p38d ablation on Golgi organization,
insulin secretion, and glucose tolerance.
p38d Negatively Regulates PKD-Mediated Stimulated
Insulin Secretion
PKD resides in the Gq protein-coupled receptor (GqPCR)
pathway, which in b cells is known to be strongly activated by
the insulin secretagogue acetylcholine (Gilon and Henquin,
2001). Indeed, activity of PKD was markedly increased upon
stimulation with the acetylcholine analog carbachol. By contrast,
exendin-4 (a GLP-1 analog) (Drucker, 2006), forskolin (Wiedenk-
eller and Sharp, 1983), and glucose did not detectably activateCell 136, 235–248, January 23, 2009 ª2009 Elsevier Inc. 241
Figure 6. p38d Suppresses PKD-Mediated Stimulated Insulin Secretion
(A) Western blot to determine the activity of protein kinase D (PKD) in INS1 cells in response to indicated stimuli using an antibody against the activatory
phosphorylation sites (serines 744 and 748) (*unspecific band).
(B) SDS-PAGE with polyacrylamide-bound Mn2+-Phos-tag to measure the activity of p38d in nonstarved INS-1 cells in response to carbachol. Phosphorylated
p38d (P-p38d) migrated slower than unmodified p38d.
(C) Western blot to determine the activity of protein kinase D (PKD) in INS1 cells stably transfected with indicated constructs in response to carbachol (*unspecific
band).
(D) Insulin secretion from INS1 cells stably expressing HA or HA-p38dF324S in response to carbachol under basal and stimulatory glucose levels (*p < 0.05 and
**p < 0.01; ns, not significant).
(E) Insulin secretion in response to basal and stimulatory glucose from MIN6 cells stably expressing shRNA against p38d or a control vector with simultaneous
siRNA-mediated knockdown of PKD1 or transfection of a scrambled siRNA (*p < 0.05, **p < 0.01, and ***p < 0.001; ns, not significant).
(F) Insulin secretion in response to basal and stimulatory glucose from INS1 cells stably expressing GFP, GFP-tagged WT, and mutated forms of PKD (*p < 0.05
and **p < 0.01).
(D–F) All experiments were performed three times independently. All error bars indicate ± SEM.PKD (Figure 6A). The activity of p38d in response to carbachol
was examined in INS1 cells with the Phos-tag technology
(Kinoshita et al., 2006). Both phosphorylated p38d and nonphos-
phorylated p38d declined in INS1 cells (Figure 6B), indicating
that carbachol-induced activation of PKD1 correlates with p38d
inhibition.
We next assessed the role of PKD1 in insulin secretion. PKD1
was specifically inactivated in INS1 cells by siRNA-mediated
knockdown with two independent oligonucleotide sequences242 Cell 136, 235–248, January 23, 2009 ª2009 Elsevier Inc.as compared to a scrambled control siRNA (Figure S11A).
Although an induction of PKD activity was only apparent upon
stimulation with carbachol, deletion of PKD1 in INS1 cells
completely blocked insulin secretion in response to both carba-
chol and glucose (Figure S11B), indicating a general requirement
of PKD1 in stimulated insulin secretion. We went on to investi-
gate whether PKD activity and insulin secretion in response to
glucose and carbachol is p38d dependent. Carbachol-stimu-
lated activation of PKD was markedly reduced in INS1 cells
expressing HA-p38dF324S compared to cells expressing HA
alone (Figure 6C). Importantly, expression of HA-p38dF324S in
INS1 cells completely blocked insulin secretion in response to
carbachol and also attenuated secretion in response to glucose
(Figure 6D).
We subsequently tested whether inactivation of PKD1
reverses insulin release in the absence of p38d to levels seen
in wild-type cells. For this purpose, we used MIN6 cells stably
expressing shRNA against p38d as well as control cells express-
ing an empty vector and simultaneously performed siRNA
against PKD1. Efficient knockdown of p38d and PKD1 was
confirmed by Western blotting (Figure 4A and Figure S12A).
Compared to control cells, MIN6 cells lacking p38d showed
enhanced insulin secretion in the presence of basal (2.8 mM)
and of stimulatory glucose levels (25 mM), whereas knockdown
of Pkd1, as seen in INS1 cells (Figure S11), led to blockage of
glucose-stimulated insulin secretion. Inactivation of Pkd1 in
MIN6 cells lacking p38d lowered insulin secretion to levels
observed in control MIN6 cells (Figure 6E).
Finally, to assess the functional relevance of p38d-dependent
PKD1 phosphorylation, we generated INS1 cells ectopically
expressing mutated forms of PKD1 (Figure S12B). Importantly,
glucose-induced insulin secretion was suppressed by expres-
sion of GFP-PKD1-DD under stimulatory glucose conditions,
whereas it was markedly increased by expression of GFP-
PKD1-AA under both basal and stimulatory glucose conditions
compared to GFP- and GFP-PKD1-WT-expressing cells
(Figure 6F). Altogether, these data suggest that p38d suppresses
PKD-mediated stimulated insulin secretion.
p38d Deficiency Protects against Insulin Resistance
and Pancreatic b Cell Failure
To challenge the insulin secretion capacity of islets, we placed
p38dD/D and p38d+/+ mice on a high-fat diet, a widely usedmodel
for insulin resistance (Biddinger and Kahn, 2006). Although
insulin sensitivity was reduced by this protocol in both geno-
types, it remained significantly better in p38dD/D compared to
p38d+/+ mice (Figure S13A). Improved insulin sensitivity in
p38dD/D mice was associated with a moderately reduced body
weight gain (Figure S13B). As expected, insulin resistance led
to a marked hyperinsulinemia in both p38dD/D and p38d+/+
mice compared to mice on a normal diet. However, p38dD/D
mice showed significantly enhanced fasting insulin levels on
a high-fat diet compared to p38d+/+ mice, indicating that they
maintain their enhanced capacity to secrete insulin also under
insulin-resistant conditions (Figure 7A). No significant differ-
ences in islet growth in p38d+/+ and p38dD/D mice in response
to a high-fat diet could be observed (Figure S14).
Overall, differences in insulin sensitivity as well as insulin levels
resulted in a significantly improved glucose tolerance in p38dD/D
mice on a high-fat diet (Figure 7B). Thus, lack of p38d provides
protection against lipid-induced glucose intolerance.
Oxidative stress is known to contribute to pancreatic b cell
loss in insulin resistance-related diabetes mellitus (Fridlyand
and Philipson, 2006). Streptozotocin (STZ)-induced oxidative
stress is a widely used model to trigger pancreatic b cell failure
in vivo (Le May et al., 2006). We confirmed that STZ activates
p38d in pancreatic b cells (Figure S15A). As expected, glucoselevels increased in p38d+/+ mice after STZ injection, reaching
up to 15 mmol/l concentrations at day 8. However, no such
increasewas observed in p38dD/Dmice, in which plasma glucose
levels remained stable and around 7 mmol/l throughout the
observation period (Figure S15B). Plasma insulin levels and
pancreatic insulin content were significantly higher in p38dD/D
mice than in p38d+/+ mice treated with STZ (Figures S15C and
S15D). The involvement of PKD in the protection of b cells in
p38dD/D mice was tested with the inhibitor U73122. In p38dD/D
mice, U73122 increased plasma glucose and lowered insulin to
the same levels as in p38d+/+ mice after STZ injections (Figures
7C–7E). The inhibitor had no additive effect in p38d+/+ mice.
TUNEL staining revealed that whereas STZ-induced hypergly-
cemia in p38d+/+ mice was associated with a high rate of b cell
apoptosis, the rate of apoptosis was 5-fold lower in p38dD/D
mice. The protective effect of lack of p38d on apoptosis was
abolished by U73122 (Figures 7F and 7G). These data raise the
interesting possibility that p38d-imposed inhibition of PKDmight
contribute to b cell dysfunction and destruction in diabetic
subjects.
DISCUSSION
A nonredundant and specific in vivo function of the d isoform of
the MAPK family p38 has not been elucidated so far. We now
provide compelling evidence that p38d represents a key regu-
lator of pancreatic b cell function. Our work supports a negative
regulatory role for p38d in stimulated insulin secretion through
inhibition of PKD1 and regulation of exocytosis. Moreover,
immoderate suppression of PKD activity by p38d may also
contribute to b cell dysfunction in diabetic subjects.
The p38d-PKD1 Pathway Regulates Stimulated Insulin
Secretion from Pancreatic b Cells
We demonstrate that ablation of p38d activates PKD1, and
thereby enhances insulin secretion and consequently improves
glucose tolerance. Furthermore, we show that the acetylcholine
analog carbachol strongly activates PKD in pancreatic b cells.
This physiological function of PKD1 can be completely blocked
by enhancement of p38d activity. Acetylcholine represents the
major neurotransmitter of the peripheral parasympathetic
nervous system, and its binding on muscarinic acetylcholine
receptors located on the pancreatic b cells potentiates secretion
of insulin (Gautam et al., 2006). Indeed, muscarinic receptors
belong to Gq protein-coupled receptors stimulating PLC to
produce inositol 1,4,5-trisphosphate (IP3) and DAG, the latter
of which activates numerous PKC family members, including
PKD (Oancea et al., 2003) (Figure 7H).
Importantly, PKD1 deletion also blocks insulin secretion in
response to glucose. PKD activity upon glucose stimulation
could not be detected in wild-type b cells. However, in b cells
lacking p38d, in which PKD activity is constitutively enhanced,
a 2-fold increase of PKD activity was seen upon glucose stimu-
lation (Figure 4A). It has been reported that glucose generates
DAG in b cells (Peter-Riesch et al., 1988). This can either occur
by a direct effect of glucose metabolism or be secondary to
glucose-induced increases in [Ca2+]i- and Ca
2+-induced activa-
tion of PLC (Thore et al., 2007) (Figure 7H). It is therefore temptingCell 136, 235–248, January 23, 2009 ª2009 Elsevier Inc. 243
Figure 7. p38d Deficiency Protects Mice from Diabetes
(A) Blood insulin levels in fasted mice with the indicated genotypes fed a high-fat diet (HF) or a normal diet (ND) after 12 weeks (*p < 0.05).
(B) Glucose tolerance test (GTT) in mice with the indicated genotypes fed a high-fat diet (HF) or a normal diet (ND) (*p < 0.05, **p < 0.01, and ***p < 0.001).
(C) Blood glucose levels in mice with the indicated genotypes treated with STZ and DMSO or U73122 (*p < 0.05).
(D) Blood insulin levels and (E) total pancreatic insulin content in mice with the indicated genotypes treated with DMSO or U73122 8 days after STZ injections.
(F) TUNEL stain of islets of mice with the indicated genotypes treated with STZ and DMSO or U73122 and of mice without treatment (w/o treatment).
(G) Quantification of TUNEL-positive cells in relation to islet area (*p < 0.05; ns, not significant).
(H) Model: Acetylcholine (Ach)- and glucose (Glc)- induced pathways leading to increased PKD activity are indicated (M3 R, muscarinic receptor subtype M3;
GLUT2, glucose transporter 2; DAG, Diacylglycerol; PLC, phospholipase C). PKD activation leads to insulin secretion and promotes b cell survival. In diabetes,
oxidative stress-induced activation of p38d might interfere with PKD-mediated signaling, leading to impaired pancreatic b cell function.
All error bars indicate ± SEM.244 Cell 136, 235–248, January 23, 2009 ª2009 Elsevier Inc.
to speculate that activity of PKD is also rising in response to
glucose in wild-type cells but is probably below our detection
limit. Altogether, our data support a key role of the p38d-PKD1
pathway in stimulated insulin secretion.
The p38d-PKD1 Pathway Regulates Proximal and Distal
Steps of Exocytosis in Pancreatic b Cells
The findings in capacitance experiments conform to functions of
the herein identified p38d target, PKD1. One of the most estab-
lished roles of PKD is to promote fission of cell surface-destined
transport carriers from the TGN (Bossard et al., 2007; Liljedahl
et al., 2001). Enhanced membrane fission at the TGN in
the absence of p38dmost likely accounts for late effects (pulses
5 to 10) seen in capacitance experiments.
Importantly, it has been demonstrated that ectopic expression
of constitutively active PKD is sufficient to promote secretion of
neurotensin, implying that PKD in addition to its function at the
TGN primes vesicles for efficient transport and immediate fusion
(Li et al., 2004). Accordingly, enhanced PKD activity might also
explain early effects (pulses 1 to 4) observed in capacitance
experiments. Indeed, a very recent report suggests that PKD-
mediated secretion of neurotensin requires its target, Kidins220,
the latter of which is proposed to regulate more distal steps of
exocytosis (Li et al., 2008). Moreover, although not specifically
reported for PKD so far, PKCs downstream of DAG were shown
to increase the efficiency of Ca2+ on insulin exocytosis indepen-
dent of a rise in cytosolic free Ca2+ levels, a mechanism that also
underlies acetylcholine-mediated insulin secretion (Gilon and
Henquin, 2001). The observed increase of exocytosis is also
reminiscent of that previously reported for the PKC/PKD acti-
vator PMA, the latter effect also being exerted distally to the
elevation of [Ca2+]i (Ammala et al., 1994).
Overall, our data indicate that stimulated insulin secretion is
increased, at least partially, through enhancement of the effi-
ciency of TGN function, a cellular mechanism, which has not
been reported so far in this context.
The p38d-PKD1 Axis Might be Pivotal in Maintaining
b Cell Function in Diabetic Conditions
In our study, we have challenged the secretory capacity of
pancreatic islets in knockout mice with a high-fat diet, which
induces peripheral insulin resistance, leading to adaptive hyper-
insulinemia. Interestingly, p38d null mice developed less severe
insulin resistance. Strikingly, p38d null mice on a high-fat diet
became hyperinsulinemic, reaching fasting insulin levels that
were significantly higher than those in high fat-fed control
mice. The relative importance of increased insulin sensitivity
and enhanced insulin secretion to the overall improved glucose
tolerance needs to be further investigated in the future.
Additionally, we have shown that p38d plays yet another key
function in the b cell: the regulation of b cell destruction during
oxidative stress, which is a key pathogenic mechnism in both,
type 1 and type 2 diabetes mellitus (Muoio and Newgard,
2008). Strikingly, p38d knockout mice were protected against
STZ-imposed oxidative stress in b cells. Importantly, this pheno-
type also appears to be dependent on PKD activity. This is in
agreement with the report demonstrating that PKD activation is
protective against oxidative stress-induced apoptosis throughactivation of NF-kB (Storz and Toker, 2003). Even though p38d
fine-tunes PKD-mediated insulin secretion in normal physiologic
settings, in pathological situations of gradually increasing
cellular oxidative stress, p38d activity might exceed and PKD
activity may drop to levels affecting insulin secretion as well as
b cell survival (Figure 7H).
There is accumulating evidence that forcing b cells to secrete
insulin by currently used drugs, including sulfonylureas, ulti-
mately results in pancreatic b cell failure (Aston-Mourney et al.,
2008). An ideal pharmacological diabetes therapy should there-
fore combine an insulinotropic effect with protection against
b cell failure. Our data suggest that pharmacological suppres-
sion of p38d might represent such an approach. Conclusively,
the p38d-PKD pathway modulates both insulin secretion and
b cell turnover and thus provides a unifying mechanism that inte-
grates these two pathogenic features of human diabetes.
EXPERIMENTAL PROCEDURES
Generation of Mice
The p38d floxed mice were generated at Lexicon Pharmaceuticals (TheWood-
lands, TX) (for details, see the Supplemental Experimental Procedures). For
generation of p38d null mice, a targeting vector harboring LoxP sites within
the 50 UTR region and intron 1-2 (floxed exon 1) as well as a neomycin resis-
tance cassette flanked by two FRT sites were electroporated into 129/SvEvBrd
(Lex-1) ES cells. Targeted ES cell clones were microinjected into C57BL/6
(albino) blastocysts to generate chimeric animals, which were bred to
C57BL/6 (albino) females, and the resulting heterozygous offspring were
bred with a protamine-Cre recombinase transgenic line to delete exon 1.
Mice heterozygous for exon 1 deletion were backcrossed five times to the
C57BL/6 background and intercrossed to generate homozygous knockout
mice. All procedures involving animals were approved by the Veterina¨ramt
des Kantons Zu¨rich and conform to the relevant regulatory standards.
Mouse Experiments
For the glucose tolerance test, 8-week-oldmale mice were fasted for 16 hr and
then injected intraperitoneally (i.p.) with glucose (2 g/kg body weight [bw]).
Glucose was measured with the Accu-Chek Aviva system from Roche. In
experiments with the PI-PLC inhibitor U73122 (Sigma), mice were injected
i.p. with U73122 (2.5 mg/kg bw) in DMSO or with DMSO 1 hr prior experiment.
Insulin tolerance tests were performed on 8-week-old ad libitum-fed male
mice injected i.p. with insulin (1 U/kg bw). Plasma insulin levels were measured
with an insulin RIA kit (Linco). STZ (150 mg/kg bw) was injected once i.p., and
blood glucose was measured each day. After 8 days, mice were sacrificed,
serumwas harvested, and the pancreaswas isolated tomeasure insulin serum
levels and insulin content, respectively. In STZ experiments with U73122, mice
were injected i.p. with U73122 (2.5 mg/kg bw) in DMSO or with DMSO only,
three times (day 1, 2, and 3) after STZ injection. Peripheral insulin resistance
was induced by feeding of mice for 12 weeks with a high-fat diet (Research
Diets, D12331). After this period, micewere subjected to insulin tolerance tests
(1 U/kg bw) as well as glucose tolerance tests (1 g/kg bw).
Islets Isolation and Insulin Secretion
Islets were isolated by collagenase perfusion (1.9 U/ml) of pancreas and
subsequent digestion for 16 min at 37C. Islets were handpicked and trans-
ferred to RPMI1640 media containing 5 mM glucose and maintained for 3 hr
prior to the experiments or dispersed in calcium-free solution and then
cultured as above. For static incubations, islets were subsequently preincu-
bated for 60 min at 37C in Krebs-Ringer bicarbonate buffer (pH 7.4), supple-
mented with 0.05% bovine serum albumin (BSA) and 2.8 mM glucose. After
preincubation, the supernatant was discarded and the islets were incubated
in buffer solution containing 2.8 or 16.7 mM glucose for 60 min at 37C. For
the rescue experiments, islets were incubated as described above but in pres-
ence of 10 mM of U73122 or 1 mM Go¨6976 or DMSO. The islets wereCell 136, 235–248, January 23, 2009 ª2009 Elsevier Inc. 245
resuspended in acid ethanol and frozen for insulin content measurements.
Insulin secretion data were expressed as percentage of pellet. Insulin secre-
tion from INS1 and MIN6 cells was performed as described for islets, and
data were normalized to nonstimulated control cells. Total insulin from
pancreas was isolated by acid-ethanol extraction. Insulin content was normal-
ized to the total weight of the pancreas.
Cell Culture, Transfection and Cell Sorting
293T and MIN6 cells were maintained in Dulbecco’s modified Eagle’s medium
(DMEM) (GIBCO, 31966) and INS1 in RPMI-1640 medium (Sigma R0883)
according to standard procedures. Transfection of vectors, shRNA-mediated
knockdown of p38d, and siRNA against PKD1 in different cell lines is explained
in detail in the Supplemental Experimental Procedures.
Immunoprecipitation and Western Blotting
Transfected 293T were lysed in lysis buffer for 10 min at 4C. After centrifuga-
tion at 13,000 rpm for 10 min, protein concentrations were measured in the
lysate. One milligram of extract was incubated with the primary antibody
(1:500) overnight at 4C, followed by addition of 25 ml of Protein A/G Plus
(Santa Cruz Biotechnology). Immobilized proteins were washed three times
and analyzed by SDS-PAGE. For the experiment in Figure 3A, INS1 cells
were stably transfected with a plasmid carrying HA-p38dF324S or the relative
empty control, lysed, and incubated with anti-HA antibody bound to agarose
beads for 2 hr at 4C. Immunoprecipitates were washed three times and
analyzed by western blotting. Western blotting was performed according to
standard procedures (for antibodies, see the Supplemental Experimental
Procedures).
In Vitro Kinase Assay
For the experiment in Figure 3B and Figure S5D, fully recombinant bacterial
(Sigma) or Sf9 cell-derived (Cell Signaling Technology) GST-tagged PKD1,
respectively, were subjected to an in vitro kinase assay with recombinant
GST-tagged p38d. For the experiment in Figure S5A, 293T cells were trans-
fected with a plasmid carrying HA-taggedWT or constitutively active p38d iso-
forms (D176A and F324S), lysed, and incubated with anti-HA antibody bound
to agarose beads for 2 hr at 4C. Immunoprecipitates were washed and incu-
bated for 30 min at 30C in kinase buffer containing 20 mM ATP, 5 mCi [g-32P]
ATP, and 2 mg recombinant HIS-tagged ATF-2 (Santa Cruz Biotechnology). For
the experiment in Figure 3D and Figure S5C, 293T cells were transfected with
human GFP-tagged PKD1-WT, PKD1-KD, or phospho mutant PKD1 expres-
sion plasmids and lysed in standard lysis buffer for 10 min at 4C, followed
by centrifugation. The cleared lysates were incubated overnight with a-GFP
sepharose (Amersham), washed three times, and used as substrates for
recombinant GST-p38d in an in vitro kinase assay, as described above. For
the experiment in Figure 3F, immunoprecipitated human GFP-tagged PKD1-
WT, GPF-PKD1-KD, or phospho mutant GPF-PKD1 were equalized and
used together with CREBtide as a substrate in an in vitro kinase assay. Kinase
activity was measured by autoradiography caused by incorporation of phos-
phate into the CREBtide peptide (KRREILSRRPSYR) at 30C with a final
concentration of 50 mM [g-32P] ATP.
Immunofluorescence
Immunofluorescence (IF) for insulin (Linco) and glucagon (Linco) was per-
formed on paraformaldehyde-fixed pancreatic sections. Relative islet area
was measured as percentage of insulin-positive staining sections. Ten
different sections per mouse were used. IF for giantin (Covance), anti-furin
convertase (Abcam), and GM130 (BD Biosciences) were performed on meth-
anol-acetone fixed INS1 and MIN6 cells and primary b cells. Islets were
dispersed in single cells as described in single-cell capacitance measure-
ments, incubated in RPMI 1640 medium containing 5 mM glucose for 2 hr in
the presence or absence of the PI-PLC inhibitor U73122 (10 mM), the PKC
inhibitor Go¨6976 (1 mM), or DMSO, and then spun onto poly-lysine-coated
slides (700 G for 5 min).
TUNEL Assay
For the detection of apoptosis, TUNEL (terminal deoxynucleotide transferase-
mediated dUTP nick end labeling) staining was performed on paraformalde-246 Cell 136, 235–248, January 23, 2009 ª2009 Elsevier Inc.hyde-fixed pancreatic sections according to the manufacturer’s instruction
(Roche). Apoptotic cells were quantified in islets area within the section. Three
independent sections per mouse were used.
Real-Time RT-PCR
RNA was extracted with TRIzol (Invitrogen). cDNA was synthesized with the
Ready-To-Go You-Prime First-Strand beads (Amersham). Primers are
indicated in the Supplemental Experimental Procedures.
LC-MS/MS
A detailed description of the protein digest, peptide analysis with liquid
chromatography-tandemmass spectrometry, and database searches is given
in the Supplemental Experimental Procedures.
Electrophysiology and Measurement of [Ca2+]i
Whole-cell currents and exocytosis were recorded and analyzed with EPC-9
patch-clamp amplifiers and the software Pulse+Pulsefit (Heka Electronic).
[Ca2+]i was assessed in freshly isolated islets with a dual wavelength PTI
system (PTI, Monmouth, NJ) fitted to an inverted microscope (for details,
see the Supplemental Experimental Procedures).
Statistical Analyses
Statistical significance was calculated with an ANOVA with post hoc Tukey’s
test and student’s unpaired t test. Significance was accepted at the level of
p < 0.05. For electron microscopy, statistical analyses are indicated in the
Supplemental Experimental Procedures.
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures, 15
figures, and two tables and can be found with article online at http://www.
cell.com/supplemental/S0092-8674(08)01493-1.
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